Table 1
Biologic start post 01/01/2010, unless specified. *All values median(IQR) or n(%) | Etanercept [N=165] | Adalimumab [N=45] | Infliximab [N=29] | Tocilizumab [N=32] | Anakinra [N=15] | Pre-2010 Etanercept [N=582] |
|---|---|---|---|---|---|---|
Female | 109 (67%) | 30 (67%) | 17 (59%) | 14 (44%) | 11 (73%) | 384 (66%) |
Age, years | 11 (8, 14) | 10 (6, 14) | 8 (5, 10) | 8 (4, 11) | 3 (2, 13) | 11 (8, 14) |
Disease duration, years | 2 (1, 5) | 4 (2, 6) | 3 (2, 6) | 1 (1, 2) | 0 (0, 1) | 4 (2, 7) |
ILAR Category | ||||||
Systemic arthritis | 5 (3%) | 1 (2%) | 1 (3%) | 28 (88%) | 15 | 70 (12%) |
Oligoarthritis | 39 (24%) | 24 (53%) | 16 (55%) | 0 | (100%) | 117 (20%) |
Polyarthritis | 83 (50%) | 9 (20%) | 9 (31%) | 3 (9%) | 0 | 253 (43%) |
Enthesitis Related Arthritis | 10 (6%) | 5 (11%) | 2 (7%) | 0 | 0 | 50 (9%) |
Psoriatic arthritis | 10 (6%) | 5 (11%) | 1 (3%) | 0 | 0 | 44 (8%) |
Other | 18 (11%) | 1 (2%) | 0 | 1 (3%) | 0 | 48 (8%) |
0 | ||||||
Concomitant MTX | 77 (47%) | 31 (69%) | 26 (90%) | 28 (88%) | 12 (80%) | 322 (55%) |
Concomitant corticosteroids | 15 (9%) | 7 (16%) | 5 (17%) | 23 (72%) | 7 (47%) | 146 (25%) |
Ever had uveitis | 7 (5%) | 31 (70%) | 21 (72%) | 0 | 0 | 54 (11%) |
CHAQ [0-3] | 1 (0, 2) | 1 (0, 1) | 0 (0, 1) | 1 (0, 2) | 2 (1, 2) | 1 (0, 2) |
JADAS-71 | 13 (8, 21) | 10 (7, 17) | 6 (3, 12) | 19 (1, 22) | 23 (7, 30) | 16 (9, 23) |